Record 2014 Annual Revenue of $1.6 billion, Up 50% Over 2013 Increased Annual Adjusted EBITDA to $253.5 million, Up 33% Over 2013 Record Quarterly Revenue of $483.5 million, Up 10% Over Third Quarter 2014
Fourth Quarter Adjusted EBITDA of $82.3 million and Adjusted Net Income of $30.5 million ($0.54 per diluted share), Up 10% and 15% Over Third Quarter 2014 HOUSTON , Feb.
Seven-fold lower incidence of VTE in patients treated with ISIS-FXI Rx compared with enoxaparin Data published in New England Journal of Medicine and featured at the American Society of Hematology annual meeting
Isis to host a webcast at 9:00 a.m. ET on Monday, December 8, 2014 CARLSBAD, Calif.
OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE:PFE) announced today
that they have entered into a worldwide agreement for the development
and commercialization of OPKO’s long-acting hGH-CTP for the treatment of
growth hormone deficiency (GHD) in adults and children, as well as for
the treatment of growth failure in children born small for gestational
age (SGA) who fail to show catch-up growth by 2 years of age.
By Reed Albergotti
Facebook Inc. (FB) said it had acquired a voice-recognition startup that claims to "turn speech into actionable data," a move that could give the social network more information for targeted advertisements.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.